You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 214 The KRASG12D(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRASG12D mutant cancer

Citation Tools

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Biomarkers, Immune Monitoring and Novel Technologies
214 The KRASG12D(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRASG12D mutant cancer

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Shifrin NT, Menard M, Courtney H, et al
214 The KRASG12D(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRASG12D mutant cancer
Journal for ImmunoTherapy of Cancer 2023;11:doi: 10.1136/jitc-2023-SITC2023.0214